All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Metreleptin
Therapeutic Area: Genetic Disease Product Name: Myalepta
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Amryt Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 08, 2021
Details:
This agreement completes the multi-regional distribution agreements with Medison, announced in February, to distribute Myalept® (metreleptin) and Lojuxta® (lomitapide) in Israel, and Juxtapid® (lomitapide) in Canada.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alpha1-Proteinase Inhibitor (Human)
Therapeutic Area: Genetic Disease Product Name: Glassia
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020
Details:
Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
